Neutralizing antibodies for the treatment of COVID-19.
Where this comes from
- Record sourced from PubMed, PMID 33293725.
- Also identified by DOI 10.1038/s41551-020-00660-2 and PMC identifier 7891858.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
Medical subject headings
- Antibodies, Neutralizing
- COVID-19
- COVID-19 Drug Treatment